As health workers in the Democratic Republic of Congo (DRC) combat an Ebola outbreak caused by the Bundibugyo strain, scientists globally are striving to create a targeted vaccine. This outbreak, which has resulted in 61 deaths and 359 confirmed cases, is particularly challenging due to the region's conflict, displacement, and inadequate healthcare resources. Researchers Teresa Lambe and Rebecca Makinson from the Oxford Vaccine Group are developing a vaccine candidate utilizing the ChADOx1 viral-vector platform, similar to the one used for the Oxford-AstraZeneca COVID-19 vaccine. On June 1, they received fast-track funding from the Coalition for Epidemic Preparedness Innovations, alongside Moderna and IAVI. The Oxford team is currently testing the vaccine on small animals while preparing for human clinical trials. Lambe emphasizes the importance of developing vaccines proactively rather than reactively, ensuring availability during outbreaks. The urgency of their work highlights the ongoing need for effective responses to emerging health crises.